Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...
About Kailera Therapeutics Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and ...
Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...
Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic ...
Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...
The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such ... Lilly’s dual GLP-1/GIP agonist. An unexpected side ...
Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback